
Two patients who have participated in clinical trials with psychedelics have founded a non-profit aimed at representing the voice of the participants of psychedelic studies and advocating for the unique safety requirements of psychedelic therapy.
As Vardit Kohn first reported in Open Foundation, Ian Roullier and Leonie Schneider recently launched PsyPA.